Logo image of MTP

MIDATECH PHARMA PLC-ADR (MTP) Stock Fundamental Analysis

USA - NASDAQ:MTP - US59564R5000 - ADR

0.2851 USD
-0.06 (-18.52%)
Last: 3/24/2023, 8:00:00 PM
0.2801 USD
-0.01 (-1.75%)
After Hours: 3/24/2023, 8:00:00 PM
Fundamental Rating

1

Overall MTP gets a fundamental rating of 1 out of 10. We evaluated MTP against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of MTP have multiple concerns. MTP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MTP has reported negative net income.
In the past year MTP has reported a negative cash flow from operations.
MTP Yearly Net Income VS EBIT VS OCF VS FCFMTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -5M -10M -15M -20M

1.2 Ratios

MTP has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTP Yearly ROA, ROE, ROICMTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTP Yearly Profit, Operating, Gross MarginsMTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

MTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
MTP has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, MTP has a worse debt to assets ratio.
MTP Yearly Shares OutstandingMTP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M
MTP Yearly Total Debt VS Total AssetsMTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -12.33, we must say that MTP is in the distress zone and has some risk of bankruptcy.
MTP has a worse Altman-Z score (-12.33) than 81.14% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that MTP is not too dependend on debt financing.
MTP has a worse Debt to Equity ratio (0.07) than 62.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -12.33
ROIC/WACCN/A
WACC6.79%
MTP Yearly LT Debt VS Equity VS FCFMTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M 40M

2.3 Liquidity

A Current Ratio of 5.28 indicates that MTP has no problem at all paying its short term obligations.
MTP has a Current ratio of 5.28. This is comparable to the rest of the industry: MTP outperforms 47.70% of its industry peers.
MTP has a Quick Ratio of 5.28. This indicates that MTP is financially healthy and has no problem in meeting its short term obligations.
MTP's Quick ratio of 5.28 is in line compared to the rest of the industry. MTP outperforms 48.65% of its industry peers.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 5.28
MTP Yearly Current Assets VS Current LiabilitesMTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.43% over the past year.
Looking at the last year, MTP shows a quite strong growth in Revenue. The Revenue has grown by 11.98% in the last year.
Measured over the past years, MTP shows a very negative growth in Revenue. The Revenue has been decreasing by -15.26% on average per year.
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.63%
Revenue 1Y (TTM)11.98%
Revenue growth 3Y-33.19%
Revenue growth 5Y-15.26%
Sales Q2Q%16.71%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTP Yearly Revenue VS EstimatesMTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M
MTP Yearly EPS VS EstimatesMTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MTP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTP Price Earnings VS Forward Price EarningsMTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTP Per share dataMTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MTP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIDATECH PHARMA PLC-ADR

NASDAQ:MTP (3/24/2023, 8:00:00 PM)

After market: 0.2801 -0.01 (-1.75%)

0.2851

-0.06 (-18.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)04-24 2023-04-24
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.98M
Revenue(TTM)645.00K
Net Income(TTM)-5367000
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.48
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0.12
BVpS1.34
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.39%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.28
Quick Ratio 5.28
Altman-Z -12.33
F-Score2
WACC6.79%
ROIC/WACCN/A
Cap/Depr(3y)40.47%
Cap/Depr(5y)39.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.63%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.98%
Revenue growth 3Y-33.19%
Revenue growth 5Y-15.26%
Sales Q2Q%16.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.58%
OCF growth 3YN/A
OCF growth 5YN/A

MIDATECH PHARMA PLC-ADR / MTP FAQ

What is the fundamental rating for MTP stock?

ChartMill assigns a fundamental rating of 2 / 10 to MTP.


What is the valuation status of MIDATECH PHARMA PLC-ADR (MTP) stock?

ChartMill assigns a valuation rating of 3 / 10 to MIDATECH PHARMA PLC-ADR (MTP). This can be considered as Overvalued.


How profitable is MIDATECH PHARMA PLC-ADR (MTP) stock?

MIDATECH PHARMA PLC-ADR (MTP) has a profitability rating of 0 / 10.